At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Trading 11-22 10:23:11 EST
0.8980
+0.0044
+0.49%
High0.9000Low0.8660Vol185.12K
Open0.8913D1 Closing0.8936Amplitude3.80%
Mkt Cap39.19MTradable Cap19.31MTotal Shares43.64M
T/O163.11KT/O Rate0.86%Tradable Shares21.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-13
Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
TIPRANKS  ·  11-13
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Tempest Therapeutics Inc : Piper Sandler Cuts Target Price to $5 From $8
THOMSON REUTERS  ·  11-13
Tempest Therapeutics Inc : Piper Sandler Cuts Target Price to $5 From $8
Tempest Therapeutics Q3 EPS $(0.41) Misses $(0.35) Estimate
Benzinga  ·  11-13
Tempest Therapeutics Q3 EPS $(0.41) Misses $(0.35) Estimate
Tempest Therapeutics Q3 EPS USD -0.41 VS. Ibes Estimate USD -0.36
THOMSON REUTERS  ·  11-13
Tempest Therapeutics Q3 EPS USD -0.41 VS. Ibes Estimate USD -0.36
BRIEF-Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma
Reuters  ·  11-12
BRIEF-Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma
Tempest Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Reuters  ·  11-04
Tempest Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
TIPRANKS  ·  10-11
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
TIPRANKS  ·  10-11
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Tempest Therapeutics Shares up 12.6% at $1.74 After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Shares up 12.6% at $1.74 After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study
Reuters  ·  10-10
BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study
Traders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-Bell
MT Newswires Live  ·  10-10
Traders Digest Consumer Inflation Measure as US Equity Futures Drop Pre-Bell
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
MT Newswires Live  ·  10-10
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell
Roche collaboration for lead asset boosts Tempest
seekingalpha  ·  10-10
Roche collaboration for lead asset boosts Tempest
Tempest Therapeutics Shares up 29% at $1.74 Premarket After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Shares up 29% at $1.74 Premarket After Agreement to Test Its Liver Cancer Drug With Roche's Therapy in Pivotal Study
Tempest Therapeutics Extends Limited Duration Stockholder Rights Plan; Shares Rise Premarket
MT Newswires Live  ·  10-10
Tempest Therapeutics Extends Limited Duration Stockholder Rights Plan; Shares Rise Premarket
BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Reuters  ·  10-10
BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Therapeutics Inc - Phase 3 Study to Start in Q1 2025
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Inc - Phase 3 Study to Start in Q1 2025
Tempest Announces Agreement With Roche to Support Advancement of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
THOMSON REUTERS  ·  10-10
Tempest Announces Agreement With Roche to Support Advancement of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Therapeutics Inc - Rights Plan to Expire After 2025 Annual Meeting Unless Approved
THOMSON REUTERS  ·  10-10
Tempest Therapeutics Inc - Rights Plan to Expire After 2025 Annual Meeting Unless Approved

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--